Clinical trials: Oligometastatic
HER2-positive Metastatic Breast Cancer, Oligometastatic Disease
Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer
This study involves two non-randomized groups of patients: the observation group and the comparison group. The comparison group will retrospectively include data on 29 patients with oligometastatic HER2-positive breast cancer who…
- Trial name
- NCT06299852
- Testing
- Trastuzumab emtansine
- Where
- Russia
- Volunteers
- 58 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Oligometastatic Disease, Metastatic Non Small Cell Lung Cancer
Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC
Standard Maintenance Therapy versus Local Consolidative Radiation Therapy and standard maintenance therapy in 1-5 sites of OligoMetastatic Non-small cell lung cancer (NSCLC): A Phase III Randomized Controlled Trial
- Trial name
- TARGET-02 (NCT05278052)
- Testing
- Local consolidative radiation therapy, Standard maintenance therapy as decided by the treating medical oncologist
- Where
- India
- Volunteers
- 190 people
- Sponsor
- Tata Memorial Hospital
Prostate Cancer, Oligometastatic Prostate Cancer
Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer
This study is a multicenter, randomized controlled phase III clinical trial (PROLONG-3) designed to evaluate the survival benefit of comprehensive radiotherapy combined with primary tumor radiotherapy versus primary tumor…
- Trial name
- PROLONG-3 (NCT07015138)
- Testing
- TRT, NTRT
- Where
- 3 sites in China
- Volunteers
- 390 people
- Sponsor
- Peking University First Hospital
Spinal Metastases, Spinal Tumor
En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.
The purpose of this clinical trial is to explore the impact of En bloc surgery and separation surgery combined with radiation therapy on the prognosis and survival of patients with spinal oligometastatic cancer, describe the…
- Conditions
- Spinal Metastases, Spinal Tumor, Radiotherapy, Malignant Bone Tumor
- Trial name
- NCT06120426
- Testing
- total en bloc spondylectomy
- Where
- China
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Shanghai Changzheng Hospital
NSCLC/Oligometastatic Cancer (Single Lung Lesion)
'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)
This is a phase II, non-randomised study examining the safety of treating high risk centrally located non-small cell lung cancer (NSCLC) tumours and single pulmonary oligometastatic lesions using radiation therapy (RT), for…
- Trial name
- SOURCE Lung (NCT04375904)
- Testing
- Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR)
- Where
- 2 sites in Ireland
- Volunteers
- 68 people
- Sponsor
- Cancer Trials Ireland
Oligometastatic Disease
Prediction of True Oligo-metastatic Disease.
In recent years, the scientific community has recognized the need to differentiate between poly- and oligo-metastatic disease (OMD) in oncology due to their distinct clinical and biological behavior.
- Trial name
- PREDICTION (NCT05806151)
- Testing
- Genetic and immunologic assessments
- Where
- Italy
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute, Naples
Oligometastatic Disease
Prospective Observational Basket Study of Stereotactic Body Radiation Therapy for OligoMetastatic Patients From Rare Tumors
This prospective observational study aims to investigate the effectiveness and safety of SBRT in the management of oligometastases from rare tumors.
- Trial name
- PROMPT (NCT05903261)
- Testing
- SBRT
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Istituto Clinico Humanitas
Colorectal Cancer
The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer
This is a prospective, single-center, single-arm phase II clinical trial. This study aims to evaluate the safety and tolerability of stereotactic ablative radiotherapy (SABR) in combination with Sintilimab, and to examine the…
- Trial name
- NCT04535024
- Testing
- Stereotactic Ablative Radiotherapy (SABR), Sintilimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Oligometastatic Disease, Bone Metastases
Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease
This is a prospective, investigator-initiated, phase II, multicentre-study, investigating the efficacy and toxicity of definitive SABR of osseous oligometastases, when pragmatically introduced into a daily clinical setting.
- Conditions
- Oligometastatic Disease, Bone Metastases, Stereotactic Body Radiotherapy
- Trial name
- NCT05101824
- Testing
- SABR
- Where
- 6 sites in Denmark, Norway
- Volunteers
- 67 people
- Sponsor
- Gitte Fredberg Persson MD PhD
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
This phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced colorectal cancer that has spread to up to 4 body sites…
- Conditions
- Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Oligometastatic Colorectal Carcinoma
- Trial name
- NCT05673148
- Testing
- Stereotactic Ablative Radiotherapy, Resection, Microwave Ablation
- Where
- 189 sites in United States, Canada
- Volunteers
- 146 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer, Metastasis
Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas
This is an interventional, open-label, non-randomised, multicentre, single-arm phase II clinical trial. Eligible patients with hepatic oligometastatic adenocarcinoma of the pancreas will receive neoadjuvant combination…
- Conditions
- Pancreatic Cancer, Metastasis, Surgery, Oligometastatic Disease
- Trial name
- HOLIPANC (NCT04617457)
- Testing
- nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)
- Where
- 11 sites in Germany
- Volunteers
- 150 people
- Sponsor
- University of Cologne
Unresectable Lung Non-Small Cell Carcinoma
A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC
This is a phase II, single-arm study to evaluate the efficacy and safety of Serplulimab plus chemotherapy as conversion treatment in patients with stage IIIB-IVA oligometastatic non-small cell lung cancer.
- Trial name
- NCT05837052
- Testing
- serplulimab plus chemotherapy as conversion treatment
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Zhejiang University
Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma
This phase II trial studies how well stereotactic body radiation therapy works in treating patients with kidney cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT03575611
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 123 people
- Sponsor
- M.D. Anderson Cancer Center
Oligometastatic Hormone Sensitive Prostate Cancer
APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer
Final results from TITAN trial showed that apalutamide plus ADT improved OS in a population of patients with metastatic hormone sensitive prostate cancer (mHSPC), if compared to ADT alone.
- Trial name
- PERSIAN (NCT05717660)
- Testing
- SBRT on all sites of metastatic disease+Apalutamide
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Prostate Cancer
RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
This is a Phase II non-blinded randomized study evaluating men with oligometastatic prostate cancer lesions randomized (1:1) to stereotactic ablative radiation therapy (SABR) versus SBAR + Radium-223.
- Trial name
- RAVENS (NCT04037358)
- Testing
- Radium-223, stereotactic ablative radiotherapy (SABR)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gastric Adenocarcinoma, Oligometastasis
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
This phase II trial studies how well chemotherapy with or without radiation or surgery works in treating participants with esophageal or gastric cancer that has spread to less than 3 places in the body (oligometastatic).
- Conditions
- Gastric Adenocarcinoma, Oligometastasis, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Cancer AJCC v7
- Trial name
- NCT03161522
- Testing
- Capecitabine, Chemotherapy, Conventional Surgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Oligometastatic Clear Cell Renal Cell Carcinoma
SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma
This is a phase II clinical trial testing whether a combination of stereotactic ablative radiotherapy (SABR), axitinib, and toripalimab is effective and safe for treating oligometastatic clear cell renal cell carcinoma (a type of…
- Trial name
- NCT07744932
- Testing
- axitinib plus toripalimab, SABR
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Hebei Medical University Fourth Hospital
Cervical Cancer Stage IV
A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer
Cervical cancer is one of the most malignant reproductive system tumors that threaten women's health, characterized by distinct HPV-driven carcinogenesis and immunosuppressive tumor microenvironment.
- Trial name
- NCT06998394
- Testing
- AK104 - Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xiangbo Wan
Gastroesophageal Cancer (GC)
First Line gastroeSOphageal metastatiC canceR primAry and disTant (if Oligometastatic) lEsions-directed Radiotherapy, a Multicentric, Phase III, Randomized Controlled Trial
The aim of the study is to evaluate the efficacy of radiotherapy on the primary site of gastroesophageal cancer and extracranial stereotactic radiotherapy on metastases before the use of standard systemic therapy, in cases of…
- Trial name
- SOCRATE (NCT06922279)
- Testing
- Radiation Therapy + standard sistemic therapy (chemoteraphy), Standard systemic therapy (chemotherapy)
- Where
- Italy
- Volunteers
- 108 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non-small Cell Lung Cancer, Oligometastatic Disease
Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery
A prospective, observational study that assesses the clinical feasibility of ctDNA-based liquid biopsy in patients with oligometastatic NSCLC receiving surgery.
- Trial name
- NCT05648370
- Testing
- ctDNA testing and whole exome sequencing
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangdong Provincial People's Hospital